Product Pipeline


Xenon is focused on advancing our ion channel neurology pipeline.

The products within our novel proprietary pipeline – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics.



Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Epilepsy
X-TOLE Clinical Trial

XEN1101

for MDD
Collaboration with Mount Sinai

XEN496

for Epilepsy
EPIK Clinical Trial

XEN007

for Orphan Neurological Indications
Investigator-led study / Absence Epilepsy

NBI-921352

for Epilepsy
Partnered with Neurocrine Biosciences

FX301

for Post-Operative Pain
Partnered with Flexion Therapeutics


Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs
Publications

See publications related to our clinical development candidates

View Publications
Partners

Find out more about collaborating with Xenon

View Partners